Granulocyte colony-stimulating factor increases CD4+ T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: results from a randomized, placebo-controlled trial
Research output: Contribution to journal › Journal article › Research › peer-review
Thirty human immunodeficiency virus (HIV)-infected patients with CD4+ T cell counts <350 cells/mm3 who had received stable, highly active antiretroviral therapy (HAART) for at least 24 weeks were randomized to receive either placebo or granulocyte colony-stimulating factor (G-CSF; 0.3 mg/mL 3 times a week) for 12 weeks. Blood samples were collected at specified time points. G-CSF treatment enhanced the total lymphocyte count (P=.002) and increased CD3+ (P=.005), CD4+ (P=.03), and CD8+ (P=.004) T cell counts as well as numbers of CD3-CD16+CD56+ NK cells (P=.001). The increases in CD4+ and CD8+ cell counts resulted from increases in CD45RO+ memory T cells and cells expressing the CD38 activation marker. Lymphocyte proliferative responses to phytohemagglutinin and Candida antigen decreased, whereas NK cell activity and plasma HIV RNA did not change during G-CSF treatment. After 24 weeks, all immune parameters had returned to baseline values. This study suggests that G-CSF treatment of HIV-infected patients receiving stable HAART increases the concentration of CD4+, CD8+, and NK cells without inducing changes in the virus load.
Original language | English |
---|---|
Journal | The Journal of Infectious Diseases |
Volume | 181 |
Issue number | 3 |
Pages (from-to) | 1148-52 |
Number of pages | 5 |
ISSN | 0022-1899 |
DOIs | |
Publication status | Published - Mar 2000 |
- Adult, Aged, CD4 Lymphocyte Count, Female, Granulocyte Colony-Stimulating Factor, HIV Infections, Humans, Interleukin-2, Killer Cells, Natural, Lymphocyte Activation, Male, Middle Aged, Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Research areas
ID: 180571948